Program
milvexian
Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.
Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.
Drug pageMilvexian: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 140 open or running | phase 2since Dec 20, 2016 | Nov 17, 2015 | none ahead |
| Johnson & Johnsonits history only | 112 open or running | phase 3since Jan 19, 2023 | Mar 25, 2019 | Dec 8, 2026phase 3 · NCT05757869 |
- Named in Bristol-Myers Squibb’s own pipeline as
milvexian
, phase 3, as of Oct 29, 2026 (source). - Named in Johnson & Johnson’s own pipeline as
milvexian
, phase 3, as of Oct 13, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentJanssen (Johnson & Johnson) develops it with Bristol Myers Squibb, worldwide, development costs and profits shared.Announced Apr 16, 2018 · Source: Johnson & Johnson, Apr 16, 2018
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 17, 2015First study: phase 1 study in ThrombosisFirst studyNCT02608970 · 104 enrolled · Belgium
- Jun 17, 2016Phase 1 study in ThrombosisNCT02807909 · 28 enrolled
- Aug 24, 2016Phase 1 study in ThrombosisNCT02902679 · 6 enrolled · United States
- Nov 7, 20162 phase 1 studies in ThrombosisNCT02959060, NCT02982707
- Dec 20, 2016Phase 2 study in AntithromboticNCT03000673 · 32 enrolled · United States
- Jun 21, 2017Phase 1 study in ThrombosisNCT03196206 · 24 enrolled · United States
- Jul 18, 2017Phase 1 study in ThrombosisNCT03224260 · 33 enrolled · United States
- Oct 30, 2017Phase 1 study in StrokeNCT03341390 · 20 enrolled · United States
- Nov 30, 2017Phase 1 study in ThrombosisNCT03362437 · 12 enrolled · United Kingdom
- Apr 16, 2018Janssen (Johnson & Johnson) develops it with Bristol Myers SquibbCo-developmentWorldwide, development costs and profits shared · announced · Johnson & Johnson
- Oct 4, 2018Phase 1 study in Healthy VolunteersNCT03698513 · 113 enrolled · United States
- Nov 13, 2018Phase 2 study in Ischemic StrokeNCT03766581 · 2,366 enrolled · United States, Argentina, Australia and more
- May 2, 2019Phase 1 study in ThrombosisNCT03939702 · 9 enrolled · United States
- Jun 9, 2020Named milvexianINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986177, JNJ-70033093
- Jul 7, 2021Phase 1 study in Healthy VolunteersNCT04965389 · 17 enrolled · United Kingdom
TargetBeta
“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study
Other programs on F11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abelacimab | anthos-therapeutics-inc | phase 3 | 8 |
| SHR-2004 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 14 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04965389Healthy Volunteers · United Kingdom | 1 | Completed | Aug 22, 2021 | 17 |
| NCT03939702Thrombosis · United States | 1 | Completed | Jul 11, 2019 | 9 |
| NCT03766581Ischemic Stroke · United States, Argentina, Australia and more | 2 | Completed | Mar 31, 2022 | 2,366 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Feb 19, 2019 | 113 |
| NCT03362437Thrombosis · United Kingdom | 1 | Completed | Dec 28, 2017 | 12 |
| NCT03341390Stroke · United States | 1 | Completed | Nov 16, 2017 | 20 |
| NCT03224260Thrombosis · United States | 1 | Completed | Nov 7, 2017 | 33 |
| NCT03196206Thrombosis · United States | 1 | Completed | Mar 4, 2018 | 24 |
| NCT03000673Antithrombotic · United States | 2 | Completed | Oct 23, 2017 | 32 |
| NCT02982707Thrombosis · United States | 1 | Completed | Sep 28, 2018 | 26 |
| NCT02959060Thrombosis | 1 | Completed | Dec 2016 | 16 |
| NCT02902679Thrombosis · United States | 1 | Completed | Jun 2017 | 6 |
| NCT02807909Thrombosis | 1 | Completed | Aug 2016 | 28 |
| NCT02608970Thrombosis · Belgium | 1 | Completed | Jul 23, 2017 | 104 |
How it is read
Names in the registry
- “BMS-986177”, 14 entries
- “Milvexian”, 6 entries
- “JNJ-70033093”, 4 entries
- “JNJ-70033093 25 mg”, 1 entry
- “JNJ-70033093 50 mg”, 1 entry
Conditions, from the studies’ own filings
- Thrombosis, 9 studies
- Ischemic Stroke, 2 studies
- Atrial Fibrillation, 1 study
- Acute Coronary Syndrome, 1 study
- Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.